Subclinical Cardiovascular Disease in Psoriatic Disease

Cardiovascular Diseases Clinical Trial

Official title: Subclinical Cardiovascular Disease in Psoriatic Disease

Status Completed

Clinical Trial Summary

This study will look at how chronic inflammation seen in psoriatic disease translates into the increased atherosclerotic and thrombotic risk and how treatment reduces this CVD risk. The Aim of this study is to 1) Evaluate the association between moderate to severe psoriatic disease and measures of vascular function. 2) Evaluate the association between moderate to severe psoriatic disease and measures of thrombotic risk. 3) Understand how traditional medications used in cardiovascular disease (CVD) prevention such as aspirin and statins affect vascular function and thrombotic risk in those with moderate to severe psoriatic disease.

Clinical Trial Description

Cardiovascular disease (CVD) remains the leading cause of death in the US. Five modifiable risk factors: smoking, hyperlipidemia, diabetes, hypertension and obesity, account for 50% of CVD mortality between the ages of 45 - 79.1 These traditional cardiac risk factors dictate who to treat with primary prevention measures but do not take into account patient-specific disease states such as psoriatic disease including psoriasis and psoriatic arthritis, which predispose to chronic inflammation. Patients with psoriatic disease have an increased risk of atherosclerotic heart disease and myocardial infarctions compared to matched controls. ;

Related Conditions & MeSH terms

• Atherosclerosis
• Atherosclerotic Cardiovascular Disease
• Cardiovascular Diseases
• Infarction
• Myocardial Infarction
• Thrombotic Vascular Disease
• Vascular Diseases

• NCT number: NCT03228017
• Study type: Interventional
• Source: NYU Langone Health
• Status: Completed
• Phase: Phase 4
• Start date: August 1, 2017
• Completion date: April 1, 2019